We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




European Funding to Advance Development of Prostate Cancer Drug

By LabMedica International staff writers
Posted on 06 Sep 2015
Print article
The development of a drug for treatment of prostate cancer has been given a boost by the recent award of a EUR 2.5 million grant to its Dutch biopharmaceutical company developer.

The drug developer, Oncodrone (Nijmegen, The Netherlands), has received a grant totaling EUR 2.5 million, which will enable it to advance its lead product, the prostate cancer drug OCD155, through preclinical development towards clinical trials and for further research into its mechanism-of-action.

OCD155 halts tumor progression by blocking epithelial to mesenchymal transition (EMT) in cancers. In the EMT process epithelial cells lose their cell-cell adhesion and develop into cancer cells with aggressive properties. Consequently, cancer cells can escape the original tumor into blood and lymphatic vessels and colonize other tissues. By blocking EMT, the cancer cell is prevented from gaining invasive and malignant properties and becomes less aggressive. OCD155 was shown to be effective in in-vivo laboratory experiments to reduce the ability of tumors to spread, reduce the tumor burden, and treat advanced stages of disease.

The grant to Oncodrone comes from the Eurostars (Brussels, Belgium) and EUREKA (Brussels, Belgium) joint program. Eurostars supports international innovative projects led by research and development-performing small- and medium-sized enterprises. EUREKA is an intergovernmental organization for pan-European research and development funding and coordination. EUREKA aims to coordinate efforts of governments, research institutes, and commercial companies concerning innovation. It does not partake in military research and follows a "bottom-up" approach to research and development funding, industry itself deciding which projects should be developed.

Henk Viëtor, CEO of Oncodrone, said, “I am delighted about this crucial grant that allows us to further develop our novel approach to treating prostate cancer towards testing in humans.”

Related Links:

Oncodrone
Eurostars
EUREKA


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.